Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells.

O. Ohno, Y. Shima, Y. Ikeda, S. I. Kondo, K. Kato, M. Toi, K. Umezawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In the course of our screening for selective growth inhibitors of human umbilical vein endothelial cells (HUVECs), we isolated sangivamycin from the culture filtrate of Streptomyces. It inhibited the growth of HUVECs at approximately 30 times lower concentration than that needed to inhibit the growth of WI-38 human fibroblasts. Structurally-related nucleosides, such as toyocamycin, tubercidin, and formycins A and B, did not show the differential inhibition. Although sangivamycin is known to inhibit protein kinase C, other protein kinase C inhibitors did not inhibit the growth of HUVECs selectively. Sangivamycin effectively inhibited S-phase induction in HUVECs, like TNP-470 and LLnL, known selective inhibitors. However, unlike them sangivamycin did not induce p21 expression. On the other hand, sangivamycin was found to inhibit DNA synthesis selectively in HUVECs. Thus, sangivamycin was shown to be a new selective growth inhibitor of HUVECs acting on DNA synthesis.

Original languageEnglish
Pages (from-to)1009-1015
Number of pages7
JournalInternational Journal of Oncology
Volume18
Issue number5
Publication statusPublished - 2001 May

Fingerprint

sangivamycin
Human Umbilical Vein Endothelial Cells
Growth
Growth Inhibitors
Protein Kinase C
Toyocamycin
Tubercidin
Protein C Inhibitor
DNA
Streptomyces
Protein Kinase Inhibitors
S Phase
Nucleosides
Fibroblasts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ohno, O., Shima, Y., Ikeda, Y., Kondo, S. I., Kato, K., Toi, M., & Umezawa, K. (2001). Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. International Journal of Oncology, 18(5), 1009-1015.

Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. / Ohno, O.; Shima, Y.; Ikeda, Y.; Kondo, S. I.; Kato, K.; Toi, M.; Umezawa, K.

In: International Journal of Oncology, Vol. 18, No. 5, 05.2001, p. 1009-1015.

Research output: Contribution to journalArticle

Ohno, O, Shima, Y, Ikeda, Y, Kondo, SI, Kato, K, Toi, M & Umezawa, K 2001, 'Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells.', International Journal of Oncology, vol. 18, no. 5, pp. 1009-1015.
Ohno O, Shima Y, Ikeda Y, Kondo SI, Kato K, Toi M et al. Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. International Journal of Oncology. 2001 May;18(5):1009-1015.
Ohno, O. ; Shima, Y. ; Ikeda, Y. ; Kondo, S. I. ; Kato, K. ; Toi, M. ; Umezawa, K. / Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. In: International Journal of Oncology. 2001 ; Vol. 18, No. 5. pp. 1009-1015.
@article{bb6c6273ff1444a491c3a8ecc73295f1,
title = "Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells.",
abstract = "In the course of our screening for selective growth inhibitors of human umbilical vein endothelial cells (HUVECs), we isolated sangivamycin from the culture filtrate of Streptomyces. It inhibited the growth of HUVECs at approximately 30 times lower concentration than that needed to inhibit the growth of WI-38 human fibroblasts. Structurally-related nucleosides, such as toyocamycin, tubercidin, and formycins A and B, did not show the differential inhibition. Although sangivamycin is known to inhibit protein kinase C, other protein kinase C inhibitors did not inhibit the growth of HUVECs selectively. Sangivamycin effectively inhibited S-phase induction in HUVECs, like TNP-470 and LLnL, known selective inhibitors. However, unlike them sangivamycin did not induce p21 expression. On the other hand, sangivamycin was found to inhibit DNA synthesis selectively in HUVECs. Thus, sangivamycin was shown to be a new selective growth inhibitor of HUVECs acting on DNA synthesis.",
author = "O. Ohno and Y. Shima and Y. Ikeda and Kondo, {S. I.} and K. Kato and M. Toi and K. Umezawa",
year = "2001",
month = "5",
language = "English",
volume = "18",
pages = "1009--1015",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells.

AU - Ohno, O.

AU - Shima, Y.

AU - Ikeda, Y.

AU - Kondo, S. I.

AU - Kato, K.

AU - Toi, M.

AU - Umezawa, K.

PY - 2001/5

Y1 - 2001/5

N2 - In the course of our screening for selective growth inhibitors of human umbilical vein endothelial cells (HUVECs), we isolated sangivamycin from the culture filtrate of Streptomyces. It inhibited the growth of HUVECs at approximately 30 times lower concentration than that needed to inhibit the growth of WI-38 human fibroblasts. Structurally-related nucleosides, such as toyocamycin, tubercidin, and formycins A and B, did not show the differential inhibition. Although sangivamycin is known to inhibit protein kinase C, other protein kinase C inhibitors did not inhibit the growth of HUVECs selectively. Sangivamycin effectively inhibited S-phase induction in HUVECs, like TNP-470 and LLnL, known selective inhibitors. However, unlike them sangivamycin did not induce p21 expression. On the other hand, sangivamycin was found to inhibit DNA synthesis selectively in HUVECs. Thus, sangivamycin was shown to be a new selective growth inhibitor of HUVECs acting on DNA synthesis.

AB - In the course of our screening for selective growth inhibitors of human umbilical vein endothelial cells (HUVECs), we isolated sangivamycin from the culture filtrate of Streptomyces. It inhibited the growth of HUVECs at approximately 30 times lower concentration than that needed to inhibit the growth of WI-38 human fibroblasts. Structurally-related nucleosides, such as toyocamycin, tubercidin, and formycins A and B, did not show the differential inhibition. Although sangivamycin is known to inhibit protein kinase C, other protein kinase C inhibitors did not inhibit the growth of HUVECs selectively. Sangivamycin effectively inhibited S-phase induction in HUVECs, like TNP-470 and LLnL, known selective inhibitors. However, unlike them sangivamycin did not induce p21 expression. On the other hand, sangivamycin was found to inhibit DNA synthesis selectively in HUVECs. Thus, sangivamycin was shown to be a new selective growth inhibitor of HUVECs acting on DNA synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0035347276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035347276&partnerID=8YFLogxK

M3 - Article

C2 - 11295049

AN - SCOPUS:0035347276

VL - 18

SP - 1009

EP - 1015

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -